Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1480954 | 1.00 | PTGDR2 (0.43) | PTGDR2LPAR2FFAR1HTTTDP1 | |
| SCHEMBL1481080 | 0.94 | PTGDR2 (0.43) | PTGDR2LPAR2FFAR1CYP2C9 | |
| SCHEMBL1481081 | 0.94 | PTGDR2 (0.43) | PTGDR2LPAR2FFAR1CYP2C9 | |
| SCHEMBL1481793 | 0.93 | LPAR2 (0.42) | PTGDR2LPAR2TDP1CYP2C9 | |
| SCHEMBL1481791 | 0.93 | LPAR2 (0.42) | PTGDR2LPAR2TDP1CYP2C9 | |
| SCHEMBL1481283 | 0.91 | PTPN1 (0.38) | PTGDR2FFAR1 | |
| SCHEMBL1481284 | 0.91 | PTPN1 (0.38) | PTGDR2FFAR1 | |
| SCHEMBL12828683 | 0.91 | LPAR2 (0.41) | PTGDR2LPAR2HTTTDP1TSHR | |
| SCHEMBL1480765 | 0.89 | MEN1 (0.37) | PTGDR2HTTTDP1 | |
| SCHEMBL1480762 | 0.89 | MEN1 (0.37) | PTGDR2HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | claimed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | PTGDR2 1829/4885LPAR2 2623/4885FFAR1 1810/4885 |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | PTGDR2 1829/4885LPAR2 2623/4885FFAR1 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.